Glossary of medical terms and key words related to EYLEA and retinal diseases. Glossary of medical terms and key words related to EYLEA and retinal diseases.

Glossary

Learn more about medical terms and key words related to EYLEA and certain retinal diseases.

A

AMSLER GRID

A simple vision test that looks like graph paper with a dot in the middle. May be used at home as a tool to help monitor vision between eye care appointments.

ANTI-VEGF (ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR)

A treatment designed to block VEGF (a protein made by the blood vessels that, at high levels, can cause blood vessels to leak fluid and also result in the growth of abnormal blood vessels).

ARTERIOSCLEROSIS

Hardening of the arteries.

B

BEADING OF VEINS

When veins in the eye have sudden narrowed areas, looking like a string of beads.

BRVO (BRANCH RETINAL VEIN OCCLUSION)

BRVO occurs when one or more veins branching out from the central retinal vein become blocked. Most cases of RVO are BRVO (8 out of 10). MEfBRVO occurs when fluid leaks into the macula as a result of the blocked retinal vein.

C

CRVO (CENTRAL RETINAL VEIN OCCLUSION)

CRVO occurs when the central retinal vein becomes blocked. MEfCRVO occurs when fluid leaks into the macula as a result of the blocked central retinal vein. CRVO makes up 2 out of every 10 diagnosed cases of RVO.

D

DIABETIC RETINOPATHY SEVERITY SCALE

The Diabetic Retinopathy Severity Scale (DRSS) is a scale doctors use to show the different stages of DR and how it progresses over time.

DILATED EYE EXAM

An exam for checking the back of the eye, including the retina, for signs of problems or changes. To see into the back of the eye, the doctor puts drops into the eye to dilate (widen) the pupil.

DME (DIABETIC MACULAR EDEMA)

A complication of DR caused by swelling in the macula.

DR (DIABETIC RETINOPATHY)

An eye disease in people with diabetes that occurs when too much blood sugar (glucose) damages the blood vessels in the retina.

E

EYE CHART

A chart for measuring visual acuity (how well a person sees) that has rows of letters that get smaller from top to bottom. A person reads the smallest letters seen. The more letters seen, the better the vision.

F

FLUORESCEIN ANGIOGRAPHY

A test in which dye is used to show the blood vessels in the back of the eye.

FUNDUS PHOTOGRAPHY

A test in which a special camera takes photos showing the inside of the back of the eye.

G

GLAUCOMA

High pressure in the eye.

L

LENS

The lens is the part of the eye that helps to focus light and images on the retina.

LOW VISION SPECIALIST

A doctor trained to give low vision examinations and prescribe low vision devices and services.

M

MACULA

The part of the retina responsible for sharp central vision.

MACULAR EDEMA

When the macula of the eye swells with fluid.

O

OPTICAL COHERENCE TOMOGRAPHY

A test that shows the layers and thickness of the retina.

P

PUPIL

The opening that controls the amount of light entering the eye.

R

RETINA

The light-sensitive tissue at the back of the eye.

S

SECTIONS OF THE EYE

Different areas of the retina that a doctor examines to evaluate Diabetic Retinopathy (DR).

V

VEGF (VASCULAR ENDOTHELIAL GROWTH FACTOR)

A protein made by the blood vessels that, at high levels, can cause blood vessels to leak fluid and also result in the growth of abnormal blood vessels.

VISUAL ACUITY TEST

Measures how well you see the letters on an eye chart.

W

WET AGE-RELATED MACULAR DEGENERATION (WET AMD)

A common eye disease in people 50 years of age and older that affects the macula, the part of the eye responsible for sharp central vision.

WHAT IS DR?

WHAT IS DME?

WHAT IS WET AMD?

WHAT IS MEfRVO?

Diabetic Retinopathy DR

Diabetes is the leading cause of new cases of blindness in people 20 to 74 years of age in the United States, and DR is the most common eye problem caused by diabetes.

Diabetic Macular Edema DME

DME is a complication of DR, which can lead to vision loss.

Wet Age-related Macular Degeneration AMD

Wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.

Macular Edema following Retinal Vein Occlusion MEfRVO

MEfRVO is a serious eye condition that can quickly get worse or lead to a loss of vision.

IMPORTANT SAFETY INFORMATION
  • EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

For U.S. Residents Only

EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2019, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591

05/2019
US-LEA-14281f(2) US-LEA-14281f(2)

 

Searching with Lea

Close
MENU